CN1511842A - Rockfish insulin-like growth factor I gene and carrier containing said gene and recombined strain and its use - Google Patents
Rockfish insulin-like growth factor I gene and carrier containing said gene and recombined strain and its use Download PDFInfo
- Publication number
- CN1511842A CN1511842A CNA021497966A CN02149796A CN1511842A CN 1511842 A CN1511842 A CN 1511842A CN A021497966 A CNA021497966 A CN A021497966A CN 02149796 A CN02149796 A CN 02149796A CN 1511842 A CN1511842 A CN 1511842A
- Authority
- CN
- China
- Prior art keywords
- gene
- insulin
- growth factor
- igf
- cabrilla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title claims abstract description 80
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 26
- 241001529596 Pontinus kuhlii Species 0.000 title abstract 5
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims abstract description 51
- 241000251468 Actinopterygii Species 0.000 claims abstract description 14
- 239000002299 complementary DNA Substances 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 12
- 210000004185 liver Anatomy 0.000 claims abstract description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 7
- 239000000654 additive Substances 0.000 claims abstract description 5
- 230000000996 additive effect Effects 0.000 claims abstract description 5
- 239000007952 growth promoter Substances 0.000 claims abstract description 5
- 239000013535 sea water Substances 0.000 claims abstract description 4
- 239000012634 fragment Substances 0.000 claims description 12
- 241000321428 Epinephelus guttatus Species 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 7
- 238000010839 reverse transcription Methods 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 230000000968 intestinal effect Effects 0.000 claims description 5
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 239000013599 cloning vector Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 2
- 101150084750 1 gene Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 abstract 1
- 241000357444 Epinephelus coioides Species 0.000 description 44
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000000137 annealing Methods 0.000 description 7
- 230000004087 circulation Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000001502 gel electrophoresis Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 3
- 102000003743 Relaxin Human genes 0.000 description 3
- 108090000103 Relaxin Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 102100023915 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108010076181 Proinsulin Proteins 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 102220369447 c.1352G>A Human genes 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241001247278 Acanthopagrus schlegelii Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The present invention discloses a kind of rockfish insulin-like growth factor I gene. The gene is gene segment with rockfish insulin-like growth factor I gene full length cDNA sequence obtained with rockfish liver total RNA as template and through RT-PCR and RACE process. The present invention also constitutes carrier and recombinant strain containing the gene. The present invention makes it possible to obtain rockfish insulin-like growth factor I recombinant protein with stable source and low cost and to prepare fish growth promoter and additive suitable for sea water fishes.
Description
Technical field
The invention belongs to gene engineering technology field, particularly a kind of cabrilla insulin-like growth factor I gene and contain the carrier and the recombinant strain of this gene, and this recombinant protein is fit to short fish growth promoter that seawater fish uses or the application in the additive in preparation.
Background technology
Insulin-like growth factor I (Insulin-like growth factor-I) is a kind of protein of being made up of 70 amino acid, because its structure is similar to proinsulin (proinsulin), so and Regular Insulin (insulin, INS), insulin like growth factor-1 I (IGF-II), Relaxin (relaxin) be called as the INS/IGF/relaxin family protein together, IGF-I has and regulates cellular metabolism, promotes cell growth, differentiation and division, suppresses necrocytosis, regulates the effect of various kinds of cell function.The growth enhancing effect of tethelin (GH) is mainly by IGF-I mediation, so IGF-I also once was known as somatomedin C (somatomedin C), and IGF-I plays an important role in postnatal growing.
Because IGF-I has important role in many-sides such as fish growth, breeding and osmotic pressure adjustings, external many scholars have set up transgenic animal model overexpression IGF-I gene, and the growth rate of IGF-I transgenic animal has showed the increase of slight (about 30%).
In recent years along with fish IGF-I research further deeply, no matter be bioactive detection of IGF-I and research, still set up the IGF-I radioimmunoassay, radioreceptor assay, or ELISA etc. needs q.s fish IGF-I albumen.Many scholars natural IGF-I albumen of once attempting to purify from blood plasma of fish or tissue is all come back after a vain attempt, and external now existing company begins scale operation gene recombination fish IGF-I albumen, but the IGF-I albumen of Epinephelus coioide is not arranged as yet.
Summary of the invention
The object of the present invention is to provide a kind of reorganization Epinephelus coioide insulin-like growth factor I gene;
Another object of the present invention is to provide the carrier that contains this gene, particularly cloning vector and expression vector;
Another object of the present invention is to provide above-mentioned carrier microorganism transformed bacterial strain;
Another object of the present invention is to provide above-mentioned recombinant protein to be fit to the short fish growth promoter of seawater fish use or the application in the additive in preparation.
Amino acid sequence analysis shows that Epinephelus coioide insulin-like growth factor I mature peptide is a former interior fragment of Epinephelus coioide insulin-like growth factor I, be equivalent to the Epinephelus coioide insulin-like growth factor I former the 45th to 112 amino acids sequences, be the B-C-A-D zone, totally 68 amino acid.Insulin-like growth factor I is former to produce this section through proteolytic ferment excision back in the course of processing, have the biological activity that promotes growth, breeding and adjusting osmotic pressure, does not have this activity and complete insulin-like growth factor I is former.
Epinephelus coioide insulin-like growth factor I full-length gene of the present invention is to be template with the cDNA that the reverse transcription of Epinephelus coioide liver total RNA obtains, obtain through PCR and the amplification of RACE method, it derives from the pairing full length gene fragment of insulin-like growth factor I structural domain on the Epinephelus coioide liver cDNA.
The IGF-I mature peptide gene order that the present invention is used to express Epinephelus coioide IGF-I recombinant protein is to be template with Epinephelus coioide insulin-like growth factor I full-length gene double-stranded DNA, obtain through the PCR method amplification, it derives from the B-C-A-D area relative gene fragment of Epinephelus coioide insulin-like growth factor I full-length gene.
IGF-I mature peptide gene order according to above-mentioned Epinephelus coioide IGF-I recombinant protein, it is the fragment of Epinephelus coioide insulin-like growth factor I full-length gene 394bp to 597bp (being equivalent to 45 to 112 amino acids) preferably, and its aminoacid sequence and coded aminoacid sequence thereof are shown in sequence table.
The present invention has also made up the carrier of the IGF-I mature peptide gene order that contains above-mentioned Epinephelus coioide IGF-I recombinant protein; The escherichia coli cloning carrier and the expression vector that particularly contain this gene.These construction of carrier are according to a conventional method, will by PCR method synthetic Epinephelus coioide insulin-like growth factor I gene through enzyme cut with separation and purification after, be linked between the corresponding restriction enzyme site of existing respective carrier, promptly be built into the required Epinephelus coioide insulin-like growth factor I expression carrier that contains.
The recombinant expression vector that the above-mentioned coli expression carrier that contains Epinephelus coioide insulin-like growth factor I gene preferably is built into by synthetic Epinephelus coioide insulin-like growth factor I gene of the present invention and coli expression carrier pRSET, called after pRSET-IGF-I.
The present invention has also made up the intestinal bacteria recombinant strain that can efficiently express Epinephelus coioide insulin-like growth factor I gene respectively with the above-mentioned corresponding expression vectors that contains Epinephelus coioide IGF-I gene.
Of the present inventionly above-mentionedly can express the bacterial strain that Epinephelus coioide insulin-like growth factor I intestinal bacteria recombinant bacterial strain preferably obtains by containing Epinephelus coioide insulin-like growth factor I expression carrier pRSET-IGF-I transformed into escherichia coli BL21, called after Escherichia coliBL21 (pRSET-IGF-I) is called for short Ecoli BL21 (pRSET-IGF-I).
Epinephelus coioide has great economic worth, and the present invention utilizes genetic engineering technique production reorganization Epinephelus coioide IGF-I albumen, and can be further as short fish growth promoter of preparation or additive.
Description of drawings
Fig. 1 and Fig. 2 are to be the gel electrophoresis analysis figure of the insulin-like growth factor I gene intermediate segment pcr amplification product of template with the cDNA that the reverse transcription of Epinephelus coioide liver total RNA obtains;
Fig. 3 is Epinephelus coioide insulin-like growth factor I gene a 3 ' RACE operational flowchart;
Fig. 4 is Epinephelus coioide insulin-like growth factor I gene 3 ' end fragment synthetic PCR gel electrophoresis analysis figure for the first time;
Fig. 5 is Epinephelus coioide insulin-like growth factor I gene 3 ' end fragment synthetic PCR gel electrophoresis analysis figure for the second time;
Fig. 6 is Epinephelus coioide insulin-like growth factor I gene 3 ' end fragment synthetic PCR gel electrophoresis analysis figure for the third time;
Fig. 7 is an Epinephelus coioide insulin-like growth factor I gene 5 ' RACE operational flowchart;
Fig. 8 is Epinephelus coioide insulin-like growth factor I gene 5 ' end fragment synthetic PCR gel electrophoresis analysis figure for the first time;
Fig. 9 is Epinephelus coioide insulin-like growth factor I gene 5 ' end fragment synthetic PCR gel electrophoresis analysis figure for the second time;
Wherein: 1. molecular weight standard; 2.PCR product; 3.pGEM-T-easy vector; 4.pGEM-T-IGF-I-clone/EcoRI.
Embodiment
The invention will be further described below in conjunction with accompanying drawing, but do not limit the present invention in any form.
Synthesizing of embodiment 1 Epinephelus coioide insulin-like growth factor I gene intermediate segment
Homology comparative result according to the cDNA sequence of the insulin-like growth factor Is of people who has delivered and various animals, to classify the design of primers template as with the cDNA total order of the nearest black porgy of Epinephelus coioide affinity, the nested degenerated primer of the synthetic cover of design has two upstream primers and a downstream primer.Article one, upstream primer (PF1) is from 20 bases of the 259th bit base [5 '-CCACACCCTCTCACT (A/G) is TGC (C/G/T)],
Second upstream primer (PF2) is from 23 bases of the 369th bit base
【5’-GTGGAGA(G/C)AG(A/G)GG(C/G/A)TTTTATTTC】，
Downstream primer (PR1) is from 20 bases of the 708th bit base
【5’-CG(A/G)CT(T/C)GAGTT(T/C)TTC(G/T)GATG】。
For the first time the cDNA that obtains with the reverse transcription of Epinephelus coioide liver total RNA of PCR is a template, and through PCR method former the 259th to 708 nucleotide sequence that increases, reaction conditions is: 95 ℃ of pre-sex change 5 minutes; Bottom is 3 circulations: 95 ℃ of sex change 30 seconds, and 80 ℃ of annealing 30 seconds, 72 ℃ were extended 1 minute; Last 72 ℃ were extended 7 minutes.For the second time PCR with the first time PCR product be template, through PCR method former the 369th to 708 nucleotide sequence that increases, reaction conditions is: 95 ℃ of pre-sex change 5 minutes; Bottom is 3 circulations: 95 ℃ of sex change 30 seconds, and 80 ℃ of annealing 30 seconds, 72 ℃ were extended 1 minute; Last 72 ℃ were extended 7 minutes.
The electrophoresis evaluation figure of twice PCR amplified production sees Fig. 1 and Fig. 2.From the visible pcr amplification for the first time of Fig. 1 the sequence of the about 450bp of one segment length, and increased the visible second time sequence of the about 340bp of a segment length of Fig. 2.
The amplified production of 340bp is connected to obtains recombinant plasmid pGEM-T-IGF-I-Clone on the pGEM-T-easy carrier.Recombinant plasmid pGEM-T-IGF-I-Clone is carried out sequencing with a pair of universal primer of pGEM-T-easy, the sequence of sequencing result and Genebank compares, and the result shows that clone's PCR product is the intermediate segment of Epinephelus coioide insulin-like growth factor I gene.
Synthesizing of embodiment 2 Epinephelus coioide insulin-like growth factor I genes 3 ' end fragment
Operation is undertaken by 3 ' RACE System for Rapid Amplification of cDNA EndsKit Protocol.According to the requirement of test kit, according to pulsating sequences Design in the middle of the IGF-I that checked order two upstream primer GSP and Nested GSP to carry out nested PCR.Article one, upstream primer (GSP) is 22 bases of middle pulsating sequence the 242nd bit base of IGF-I from having checked order
【5’-TAGGACAGCACAGCAGCCAGAC】，
Second upstream primer (Nested GSP) is from 22 bases of the 280th bit base
【5’-AGAGACCTTTACCTGGACATAG】。Idiographic flow is seen Fig. 3:
For the first time the cDNA that obtains with the reverse transcription of Epinephelus coioide liver total RNA of PCR is a template, and through PCR method former the 369th nucleotide sequence to 3 ' poly A end that increase, reaction conditions is: 95 ℃ of pre-sex change 5 minutes; Bottom is 3 circulations: 95 ℃ of sex change 30 seconds, and 80 ℃ of annealing 30 seconds, 72 ℃ were extended 1 minute; Last 72 ℃ were extended 7 minutes.For the second time PCR with the first time PCR product be template, through PCR method former the 611st nucleotide sequence to 3 ' poly A end that increase, reaction conditions is: 95 ℃ of pre-sex change 5 minutes; Bottom is 3 circulations: 95 ℃ of sex change 30 seconds, and 80 ℃ of annealing 30 seconds, 72 ℃ were extended 1 minute; Last 72 ℃ were extended 7 minutes.For the third time PCR with the second time PCR product be template, through PCR method former the 649th nucleotide sequence to 3 ' poly A end that increase, reaction conditions is: 95 ℃ of pre-sex change 5 minutes; Bottom is 3 circulations: 95 ℃ of sex change 30 seconds, and 80 ℃ of annealing 30 seconds, 72 ℃ were extended 1 minute; Last 72 ℃ were extended 7 minutes.
The electrophoresis evaluation figure of three pcr amplification products sees Fig. 4, Fig. 5 and Fig. 6.
The amplified production of 750bp and 250bp is connected to obtains recombinant plasmid pGEM-T-IGF-I-3 '-1 and pGEM-T-IGF-I-3 '-2 on the pGEM-T-easy carrier.The a pair of universal primer of recombinant plasmid pGEM-T-IGF-I-3 '-1 and pGEM-T-IGF-I-3 '-2 usefulness pGEM-T-easy is carried out sequencing, the sequence of sequencing result and Genebank compares, the result show clone's 250bp product be Epinephelus coioide insulin-like growth factor I 3 ' end group because of.
Synthesizing of embodiment 3 Epinephelus coioide insulin-like growth factor I gene 5 ' end fragments
Operation is undertaken by 5 ' RACE System for Rapid Amplification of cDNA EndsKit Protocol.According to the requirement of test kit, according to pulsating sequences Design in the middle of the IGF-I that checked order downstream primer G-GSP1 to carry out reverse transcription and two downstream primer S-GSP2 and Nested S-GSP to carry out nested PCR.Article one, downstream primer (G-GSP1) is 17 bases of middle pulsating sequence the 317th bit base of IGF-I from having checked order
【5’-CTTGAAGGATGAATGACTAT】，
Second downstream primer (S-GSP2) is from 19 bases of the 89th bit base
【5’-GAAGCAGCATTCGTCCACA】，
Article three, downstream primer (Nested S-GSP) is from 19 bases of the 44th bit base
【5’-GCCATAGCCTGTTGGTTTA】。
Idiographic flow is seen Fig. 7.
For the first time the cDNA that obtains with the reverse transcription of Epinephelus coioide liver total RNA of PCR is a template, and through PCR method former the 459th nucleotide sequence to 5 ' end that increase, reaction conditions is: 95 ℃ of pre-sex change 5 minutes; Bottom is 3 circulations: 95 ℃ of sex change 30 seconds, and 80 ℃ of annealing 30 seconds, 72 ℃ were extended 1 minute; Last 72 ℃ were extended 7 minutes.For the second time PCR with the first time PCR product be template, through PCR method former the 414th nucleotide sequence to 5 ' end that increase, reaction conditions is: 95 ℃ of pre-sex change 5 minutes; Bottom is 3 circulations: 95 ℃ of sex change 30 seconds, and 80 ℃ of annealing 30 seconds, 72 ℃ were extended 1 minute; Last 72 ℃ were extended 7 minutes.
The electrophoresis evaluation figure of secondary PCR amplified production sees Fig. 8 and Fig. 9.
The amplified production of 650bp and 400bp is connected to obtains recombinant plasmid pGEM-T-IGF-I-5 '-1 and pGEM-T-IGF-I-5 '-2 on the pGEM-T-easy carrier.The a pair of universal primer of recombinant plasmid pGEM-T-IGF-I-5 '-1 and pGEM-T-IGF-I-5 '-2 usefulness pGEM-T-easy is carried out sequencing, the sequence of sequencing result and Genebank compares, the result show clone's 650bp product be Epinephelus coioide insulin-like growth factor I 5 ' end group because of.
The splicing of embodiment 4 Epinephelus coioide insulin-like growth factor I full length gene sequences
The IGF-I coded slices, 5 ' RACE segment and 3 ' the RACE segment that have checked order are spliced, obtain the total length of the IGF-I gene of Epinephelus coioide, be 925bp, and begin from the initiation codon of 262bp, finish to its termination codon, infer its aminoacid sequence.The aminoacid sequence of IGF-I full length gene and supposition is seen sequence table.
Sequence table
＜110〉Zhongshan University
＜120〉cabrilla insulin-like growth factor I gene and contain carrier and the recombinant strain and the application thereof of this gene
<130>
<140>
<141>
<160>2
<170>PatentIn?Ver.2.1
<210>1
<211>925
<212>DNA
<220>
<221>CIDS
<222>(262)..(819)
<220>
<221>sig_peptide
<222>(262)..(393)
<220>
<221>polyA_signal
<222>(909)..(925)
<400>1
gggggggggg?ggaggcaaat?gctgccccag?ctgtttcctg?ttgaaaatgt?ctgtgtaatg?60
tagataaatg?tgagggattt?tctctctaaa?tccgtctcct?gttcgctaaa?tctcacttct?120
ccaaaacgag?cctgcgcaat?ggaacaaagt?cggaatattg?agatgtgaca?ttgcccgcat?180
ctcatcctct?ttctccccgt?tttttaatga?cttcaaacaa?gttcattttc?gccgggcttt?240
gtcttgcgga?gacccgtggg?g?atg?tct?agc?gct?ctt?tcc?ttt?cag?tgg?cat 291
Met?Ser?Ser?Ala?Leu?Ser?Phe?Gln?Trp?His
1 5 10
tta?tgt?gat?gtc?ttc?aag?agt?gcg?atg?tgt?tgt?atc?tcc?tgt?agccac 339
Leu?Cys?Asp?Val?Phe?Lys?Ser?Ala?Met?Cys?Cys?Ile?Ser?Cys?Ser?His
15 20 25
acc?ctc?tca?cta?ctg?ctg?tgc?gtc?ctc?acc?ctg?act?ccg?acg?gca?aca 387
Thr?Leu?Ser?Leu?Leu?Leu?Cys?Val?Leu?Thr?Leu?Thr?Pro?Thr?Ala?Thr
30 35 40
ggg?gcg?ggc?cca?gag?acc?ctg?tgc?ggg?gcg?gag?ctg?gtc?gac?acg?ctg 435
Gly?Ala?Gly?Pro?Glu?Thr?Leu?Cys?Gly?Ala?Glu?Leu?Val?Asp?Thr?Leu
45 50 55
cag?ttt?gtg?tgt?gga?gag?aga?ggc?ttt?tat?ttc?agt?aaa?cca?aca?ggc 483
Gln?Phe?Val?Cys?Gly?Glu?Arg?Gly?Phe?Tyr?Phe?Ser?Lys?Pro?Thr?Gly
60 65 70
tat?ggc?ccc?aat?gta?cgg?cgg?tca?cgt?ggc?att?gtg?gac?gaa?tgc?tgc 531
Tyr?Gly?Pro?Asn?Val?Arg?Arg?Ser?Arg?Gly?Ile?Val?Asp?Glu?Cys?Cys
75 80 85 90
ttc?caa?agc?tgt?gag?ctg?cgg?cgc?ctg?gag?atg?aac?tgt?gca?cct?gcc 579
Phe?Gln?Ser?Cys?Glu?Leu?Arg?Arg?Leu?Glu?Met?Asn?Cys?Ala?Pro?Ala
95 100 105
aag?act?agc?aag?gct?gct?cgc?tct?gtg?cgt?gca?cag?cgc?cac?aca?gac 627
Lys?Thr?Ser?Lys?Ala?Ala?Arg?Ser?Val?Arg?Ala?Gln?Arg?His?Thr?Asp
110 115 120
atg?ccg?aga?gca?ccc ~?gtt?agt?acc?gca?ggg?cac?aaa?gtg?gac?aaa 675
Met?Pro?Arg?Ala?Pro?L Val?Ser?Thr?Ala?Gly?His?Lys?Val?Asp?Lys
125 130 135
ggc?aca?gag?cgt?agg?aca?gca?cag?cag?cca?gac?aag?aca?aaa?aac?aag 723
Gly?Thr?Glu?Arg?Arg?Thr?Ala?Gln?Gln?Pro?Asp?Lys?Thr?Lys?Asn?Lys
140 145 150
aag?aga?cct?tta?cct?gga?cat?agt?cat?tca?tcc?ttc?aag?gaa?gtg?cat 771
Lys?Arg?Pro?Leu?Pro?Gly?His?Ser?His?Ser?Ser?Phe?Lys?Glu?Val?His
155 160 165 170
cag?aaa?aac?tca?agt?cga?ggc?aac?acg?ggg?ggc?aga?aat?tac?aga?atg 819
Gln?Lys?Asn?Ser?Ser?Arg?Gly?Asn?Thr?Gly?Gly?Arg?Asn?Tyr?Arg?Met
175 180 185
tagggaaggt?gcgaatggac?aaatgcccag?caacttggga?agagagaagg?gagtggcctt?879
acctggtacc?cctgtggaat?ggttcactgt?aaaaaaaaaa?aaaaaa 925
<210>2
<211>186
<212>PRT
<400>2
Met?Ser?Ser?Ala?Leu?Ser?Phe?Gln?Trp?His?Leu?Cys?Asp?Val?Phe?Lys
1 5 10 15
Ser?Ala?Met?Cys?Cys?Ile?Ser?Cys?Ser?His?Thr?Leu?Ser?Leu?Leu?Leu
20 25 30
Cys?Val?Leu?Thr?Leu?Thr?Pro?Thr?Ala?Thr?Gly?Ala?Gly?Pro?Glu?Thr
35 40 45
Leu?Cys?Gly?Ala?Glu?Leu?Val?Asp?Thr?Leu?Gln?Phe?Val?Cys?Gly?Glu
50 55 60
Arg?Gly?Phe?Tyr?Phe?Ser?Lys?Pro?Thr?Gly?Tyr?Gly?Pro?Asn?Val?Arg
65 70 75 80
Arg?Ser?Arg?Gly?Ile?Val?Asp?Glu?Cys?Cys?Phe?Gln?Ser?Cys?Glu?Leu
85 90 95
Arg?Arg?Leu?Glu?Met?Asn?Cys?Ala?Pro?Ala?Lys?Thr?Ser?Lys?Ala?Ala
100 105 110
Arg?Ser?Val?Arg?Ala?Gln?Arg?His?Thr?Asp?Met?Pro?Arg?Ala?Pro?Lys
115 120 125
Val?Ser?Thr?Ala?Gly?His?Lys?Val?Asp?Lys?Gly?Thr?Glu?Arg?Arg?Thr
130 135 140
Ala?Gln?Gln?Pro?Asp?Lys?Thr?Lys?Asn?Lys?Lys?Arg?Pro?Leu?Pro?Gly
145 150 155 160
His?Ser?His?Ser?Ser?Phe?Lys?Glu?Val?His?Gln?Lys?Asn?Ser?Ser?Arg
165 170 175
Gly?Asn?Thr?Gly?Gly?Arg?Ash?Tyr?Arg?Met
180 185
Claims (9)
1, a kind of cabrilla insulin-like growth factor I gene, gene order and aminoacid sequence are shown in sequence table.
2, cabrilla insulin-like growth factor I gene as claimed in claim 1, it is characterized in that it is is template with the cDNA that the reverse transcription of cabrilla liver total RNA obtains, the gene fragment that obtains through PCR and the amplification of RACE method with cabrilla insulin-like growth factor I full length cDNA sequence.
3, a kind of cloning vector is characterized in that containing the described cabrilla insulin-like growth factor I of claim 1 gene.
4, cloning vector as claimed in claim 3 is characterized in that this carrier is escherichia coli cloning carrier pGEMT-IGF-I.
5, a kind of recombinant strain is characterized in that it being to change formed intestinal bacteria recombinant strain pGEMT-IGF-I-DH5 α among the intestinal bacteria E.coli.DH5 α over to by the described cloning vector pGEMT-IGF-I of claim 4.
6, a kind of expression vector is characterized in that containing the described cabrilla insulin-like growth factor I of claim 1 gene.
7, expression vector as claimed in claim 6 is characterized in that this carrier is coli expression carrier pRSET-IGF-I.
8, a kind of recombinant strain is characterized in that it being to change formed intestinal bacteria recombinant strain pRSET-IGF-I-BL21 in the e. coli bl21 (DE3) over to by the described expression vector pRSET-IGF-I of claim 7.
9, the cabrilla insulin-like growth factor I recombinant protein of claim 1 is fit to the short fish growth promoter of seawater fish use or the application in the additive in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021497966A CN1511842A (en) | 2002-12-31 | 2002-12-31 | Rockfish insulin-like growth factor I gene and carrier containing said gene and recombined strain and its use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021497966A CN1511842A (en) | 2002-12-31 | 2002-12-31 | Rockfish insulin-like growth factor I gene and carrier containing said gene and recombined strain and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1511842A true CN1511842A (en) | 2004-07-14 |
Family
ID=34233796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021497966A Pending CN1511842A (en) | 2002-12-31 | 2002-12-31 | Rockfish insulin-like growth factor I gene and carrier containing said gene and recombined strain and its use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1511842A (en) |
-
2002
- 2002-12-31 CN CNA021497966A patent/CN1511842A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101063104A (en) | Engineering bacterium producing 5-glycyl ethylformic acid and construction method thereof | |
| CN1320117C (en) | Adiponectin-Glucagon-like peptide-1-like peptide recombinant protein expression vector and construction | |
| CN1924006A (en) | Anti-glioma peptide of scorpion, preparation method and application thereof | |
| CN1062014C (en) | Recombinant gene coding for human alpha interferon and expression vector thereof, ETC. | |
| CN1654656A (en) | FenneropenaeusChinensis Crustin gene and coded protein and cloning method therefor | |
| CN1192103C (en) | Method for producing phytase | |
| CN100344758C (en) | Antibacterial peptide gene of Chinese prawn containing single whey acidic protein structure domain and its coded antibacterial peptide and application | |
| CN1908016A (en) | Fusion protein with protein transduction structure field TAT-PTD and application thereof | |
| CN1236059C (en) | Grouper insulin-like growth factor II gene, carrier and recombinant strain containing the gene and application thereof | |
| CN1511842A (en) | Rockfish insulin-like growth factor I gene and carrier containing said gene and recombined strain and its use | |
| CN1873006A (en) | Method for producing recombined human proinsulin | |
| CN1810972A (en) | Lefteye flounder disease resistance related MHC gene marker and subsidiary breeding method | |
| CN100336907C (en) | Recombinant human platelet auxin/dry cell factor fusion protein and preparation thereof | |
| CN1238378C (en) | An antibiotic peptide and its coded sequence and use | |
| CN1752210A (en) | Chicken interferon gamma, preparing process and use thereof | |
| CN101037692A (en) | Method for expressing human insulin by using plant seed oil body | |
| CN1803846A (en) | Hybrid protein of p53 protein epitope(SQAMDDLMLS) and filobactivirus gene 8 protein and application thereof | |
| CN1300313C (en) | Clone of gene MAC30 related to pig backfat thickness and its use in mark-assisted selection | |
| CN100336906C (en) | Lipase gene sequence and its application in yeast | |
| CN101063132A (en) | Lateolabrax interleukins 8 gene order | |
| CN1810830A (en) | HIV-1 yesisting polypeptide C22, its coding sequence and prepn process | |
| CN1482253A (en) | Growth hormone gene of southern siluroid | |
| CN1740320A (en) | Fenneropenaeus chinensis Anti-LPS factor gene and cloning process thereof | |
| CN100344763C (en) | G-type lysozyme gene of Argopecten irradians and encoded protein and cloning method thereof | |
| CN1194092C (en) | Medusa cystatin gene, and expression and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |